drugset

drugset / Trial / NCT00051285

ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"

NCT00051285 ↗

Phase 3 Terminated 1800 enrolled Gilead Sciences

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if low-dose enoximone therapy is an effective treatment for advanced chronic heart failure.

Timeline

Start: 2002-02
Primary completion: 2005-06
Completion: 2005-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enoximone	Small molecule	50 mg	Oral

Indications